| Symbol | ZVSA |
|---|---|
| Name | ZYVERSA THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 33326 United States FL 2200 N. Commerce Parkway Suite 208 |
| Telephone | (754) 231-1688 |
| Fax | — |
| — | |
| Website | https://www.zyversa.com/ |
| Incorporation | US |
| Incorporated On | 2021 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | CBIZ CPAs P.C.; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001859007 |
| Description | ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. Additional info from OTC: |
No news found.